Application of flvcr2-as1 as a biomarker and therapeutic target for oral squamous cell carcinoma

By studying the biological mechanism of FLVCR2-AS1, it was found that FLVCR2-AS1 is expressed at low levels and overexpressed in oral squamous cell carcinoma, which solves the problem of limited treatment methods for oral squamous cell carcinoma in existing technologies and enables early diagnosis and effective treatment.

CN122104889APending Publication Date: 2026-05-29ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY
Filing Date
2026-02-12
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current technologies offer limited treatment options for oral squamous cell carcinoma, resulting in poor prognosis and a high risk of recurrence, metastasis, and drug resistance. Furthermore, there is a lack of specific lncRNA diagnostic markers and therapeutic targets.

Method used

By studying the biological mechanism of FLVCR2-AS1, we found that it is expressed at low levels in oral squamous cell carcinoma, and that overexpression of FLVCR2-AS1 can inhibit cell migration and invasion. We developed FLVCR2-AS1 as a diagnostic biomarker and therapeutic target, and promoted its expression using specific primers, probes, antibodies, recombinant viruses and small molecule activators.

Benefits of technology

FLVCR2-AS1 can be used as a diagnostic biomarker for early diagnosis and prognostic assessment, and as a therapeutic target, it can inhibit cell migration and invasion, improve treatment efficacy and prognosis, and provide new treatment strategies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122104889A_ABST
    Figure CN122104889A_ABST
Patent Text Reader

Abstract

The application relates to application of FLVCR2-AS1 as a biomarker and therapeutic target of oral squamous cell carcinoma, and belongs to the technical field of biological medicine. The application provides application of FLVCR2-AS1 as a biomarker in preparation of a product for diagnosing oral squamous cell carcinoma, wherein the nucleotide sequence of the FLVCR2-AS1 is shown in SEQ ID NO:1. It is found and identified in the application that FLVCR2-AS1 is specifically lowly expressed in oral squamous cell carcinoma tissues and cell lines, and the expression level is significantly related to the prognosis of patients. Further research finds that overexpression of FLVCR2-AS1 can effectively inhibit the migration and invasion ability of oral squamous cell carcinoma cells. These results prove that FLVCR2-AS1 is a novel molecular target with clinical application potential for oral squamous cell carcinoma.
Need to check novelty before this filing date? Find Prior Art